ClinicalTrials.gg
RecruitingNCT06852014Updated Sep 2, 2025

Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study

An interventional study of Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B and Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A in Pancreatic Cancer, Adult and Cephalic Duodenopancreatectomy, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Malnutrition is a common challenge in patients with pancreatic cancer undergoing cephalic pancreaticoduodenectomy (CPD), impacting postoperative recovery and overall prognosis. Nutritional support plays a crucial role in optimising metabolic, inflammatory, and digestive outcomes. This randomised, double-blind, crossover clinical trial aims to evaluate the effects of Peptamen 1.6, a hydrolysed whey protein-based enteral formula, compared to Resource HP/HC, a high-protein and high-calorie polymeric formula, in malnourished or at-risk patients with pancreatic cancer undergoing PD.

The study comprises both in vivo and in vitro analyses. The in vivo component will assess the impact of Peptamen 1.6 on digestive tolerance, amino acid absorption, nutritional status, metabolic profile, inflammatory markers, and gut microbiota composition. The in vitro component will utilise human intestinal organoid models to explore how enteral nutrition formulations influence intestinal permeability and metabolism, with a focus on microbiota interactions.

Primary outcomes include improvements in metabolic status, assessed through serum biomarkers (albumin, immune markers, intestinal permeability, and myosin profile), inflammatory status via peripheral blood mononuclear cells (PBMCs), and microbiota shifts in faecal samples. Additionally, adherence to treatment, digestive tolerance, and changes in body composition will be monitored using bioelectrical impedance, dynamometry, and functional mobility tests.

By elucidating the mechanisms through which different enteral nutrition strategies influence clinical, physiological, and molecular parameters, this study aims to enhance personalised nutritional interventions for patients with pancreatic cancer. The findings could contribute to optimising nutritional support strategies, ultimately improving patient outcomes following CPD.

02

Conditions studied

  • Pancreatic Cancer, Adult
  • Cephalic Duodenopancreatectomy

Keywords

  • Pancreatic cancer
  • malnutrition
  • pancreaticoduodenectomy
  • oral nutritional supplement
  • gut microbiota
  • organoids
03

In context

Pancreatic cancer, adult

25 studies on the registry are indexed under Pancreatic cancer, adult; 18 are open to participants now.

This study's planned enrollment of 20 is below the median of 90 across 17 interventional studies indexed under Pancreatic cancer, adult.

Browse Pancreatic cancer, adult studies →

Lead sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud is the lead sponsor of 72 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory patients who are malnourished or at risk of malnutrition, with a confirmed diagnosis of neoplasms of the periampullary region, pancreas, and duodenum, or pancreatic cancer, and who have undergone cephalic pancreaticoduodenectomy (CPD).
  • No prior treatment (preoperative chemotherapy or radiotherapy): Patients must not have received neoadjuvant therapy as these treatments can affect metabolism, nutritional status, and gut microbiota, potentially interfering with the objectives of the study's nutritional intervention.

Exclusion criteria

Exclusion Criteria:

  • Refusal to sign : Informed consent is a mandatory requirement for study participation. Any patient unwilling to participate voluntarily will be excluded.
  • Patients who underwent surgery more than three months ago will be excluded, as the nutritional intervention must begin in the immediate postoperative period to adequately evaluate its impact on nutritional and metabolic status.
  • Presence of severe cardiac disease, nephropathy, or other severe comorbidities: Conditions such as severe cardiac disease, renal failure, or comorbidities that could induce malnutrition or impair the patient's ability to tolerate nutritional treatment will be exclusion criteria. These conditions may interfere with assessing the effects of nutritional supplementation in the context of pancreatic cancer treatment.
  • Diarrhoea associated with antibiotics, laxatives, or osmotically active agents: Diarrhoea caused by medications may alter nutrient absorption and affect tolerance to the nutritional supplement, potentially skewing results attributable solely to the nutritional intervention.
  • Treatment with other nutritional support: Patients receiving other oral nutritional supplement, enteral or parenteral nutrition will be excluded, as interactions with the studied formula could confound the efficacy results of the study's nutritional intervention.
  • Pregnancy or possibility of becoming pregnant.
  • Type 1 or Type 2 diabetes with >8%.
  • Galactosaemia, fructosaemia, or allergies to components of the nutritional supplement.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    EXPERIMENTAL GROUP A (Nutritional supplement order A --> B)

    Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B

  • Experimental
    EXPERIMENTAL : EXPERIMENTAL GROUP B (Nutritional supplement order B --> A)

    Dietary Supplement: Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A

Interventions

  • Dietary supplementDietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B

    Intervention group will receive a nutritional formula A and, after 1-week washout period, will receive a nutritional formula B

  • Dietary supplementDietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A

    Intervention group will receive a nutritional formula B and, after 1-week washout period, will receive a nutritional formula A

06

What researchers measure

Primary outcomes

  1. Adherence to nutritional treatment

    Categorized based on the average daily consumption compared to the prescribed volume (200 ml per bottle): * Full content (200 ml/bottle) * 2/3 content (150 ml/bottle) * 1/2 content (100 ml/bottle) * 1/4 content (50 ml/bottle) Patients will self-report their average daily consumption (ml/day).

    Time frame: At weeks 6 and 13

  2. Natural food intake

    Patients will report their food intake over the previous week, categorized into quartiles (%) relative to: * Pre-illness consumption * Perceived normal intake for patients without supplementation * ALL -100% * 3/4 - 75% * HALF - 50% * ¼ - 25% * NONE - 0%

    Time frame: At weeks 6 and 13

  3. Tolerance to nutritional treatment

    Evaluated based on the frequency of gastrointestinal symptoms (e.g., nausea, vomiting, reflux, abdominal pain, flatulence, satiety, constipation, and stomach heaviness) within two hours of supplement consumption. Symptoms classified as: * Never * Rarely * Sometimes * Frequently * Always Bivariate analysis will classify tolerance as: * Good (no symptoms) * Poor (presence of any gastrointestinal symptoms)

    Time frame: At weeks 6 and 13

  4. Change in aminoacids: Ala, Glu, Asp, Pro, Phe, Leu/Ile, Val, Tyr, Met, Cit, Arg, Gly, and Orn

    Aminoacids measured in µmol/L

    Time frame: At baseline and in weeks 6, 7, and 13

  5. Change in IL-6 and TNF-alpha RNA expression

    IL-6 and TNF-alpha measured from Peripheral blood mononuclear cell (PBMC)

    Time frame: At baseline and in weeks 6, 7, and 13

Secondary outcomes

  1. Doses of pancreatic enzyme replacement therapy

    Measured in International Unit per day (IU/day)

    Time frame: Only at baseline

  2. Stool characteristics

    The number and type of stools will be assessed using the Kings Stool Chart, a standardized tool that classifies stool consistency and form to evaluate digestive function alterations. * Number of bowel movements: A numerical field to record the daily count. * Type of bowel movements: A categorical field with options ranging from 1 to 7, based on the King's Stool Chart. * Variability in type: A binary field (0 = No, 1 = Yes) to indicate whether there is variation.

    Time frame: At baseline and in weeks 6, 7, and 13

  3. Symptoms of anxiety and depression

    Measured using the Hospital Anxiety and Depression Scale (HADS), which consists of two subscales: HADS-Anxiety (HADSA) and HADS-Depression (HADSD) Interpretation of scores: * 0-7: Normal. * 8-10: Suggests the presence of mood disorders. * ≥11: Indicates a probable mood disorder.

    Time frame: At baseline and in weeks 6, 7, and 13

  4. Nutritional status

    Evaluated using the Subjective Global Assessment (SGA) and Global Leadership Initiative on Malnutrition (GLIM) criteria, both validated tools for classifying malnutrition severity. Patients will be categorized as at risk of malnutrition or having moderate or severe malnutrition based on results.

    Time frame: At baseline and in weeks 6, 7, and 13

  5. Change in Phase angle (PhA) (Vectorial Bioimpedance Analysis (BIVA))

    Phase angle (PhA) measured in degrees (º)

    Time frame: At baseline and in weeks 6, 7, and 13

  6. Change in total body water (TBW) (Vectorial Bioimpedance Analysis (BIVA))

    Total body water (TBW) measured in liters (l)

    Time frame: At baseline and in weeks 6, 7, and 13

  7. Change in extracellular water (ECW) (Vectorial Bioimpedance Analysis (BIVA))

    Extracellular water (ECW) measured in liters (l)

    Time frame: At baseline and in weeks 6, 7, and 13

  8. Change in intracellular water (ICW) (Vectorial Bioimpedance Analysis (BIVA))

    Intracellular water (ICW) measured in liters (l)

    Time frame: At baseline and in weeks 6, 7, and 13

  9. Change in Fat-free mass (FFM) (Vectorial Bioimpedance Analysis (BIVA))

    Fat-free mass (FFM) measured in kilograms (kg) and percentage (%)

    Time frame: At baseline and in weeks 6, 7, and 13

  10. Change in Fat mass (FM) (Vectorial Bioimpedance Analysis (BIVA))

    Fat mass (FM) measured in kilograms (kg) and percentage (%)

    Time frame: At baseline and in weeks 6, 7, and 13

  11. Change in Body cell mass (BCM) (Vectorial Bioimpedance Analysis (BIVA))

    Body cell mass (BCM) measured in kilograms (kg)

    Time frame: At baseline and in weeks 6, 7, and 13

  12. Change in appendicular skeletal muscle mass (ASMM) (Vectorial Bioimpedance Analysis (BIVA))

    Appendicular skeletal muscle mass (ASMM) measured in kilograms (kg)

    Time frame: At baseline and in weeks 6, 7, and 13

  13. Change in skeletal muscle index (SMI) (Vectorial Bioimpedance Analysis (BIVA))

    Skeletal muscle index (SMI) measured in kilogram per square meter (kg/m²)

    Time frame: At baseline and in weeks 6, 7, and 13

  14. Change in hydration (Vectorial Bioimpedance Analysis (BIVA))

    Hydration measured in percentage (%)

    Time frame: At baseline and in weeks 6, 7, and 13

  15. Change in resistance (Vectorial Bioimpedance Analysis (BIVA))

    Resistance measured in ohms (Ω)

    Time frame: At baseline and in weeks 6, 7, and 13

  16. Change in reactance (Vectorial Bioimpedance Analysis (BIVA))

    Reactance measured in ohms (Ω)

    Time frame: At baseline and in weeks 6, 7, and 13

  17. Handgrip dynamometry

    * Device: Jamar hydraulic dynamometer * Measurement: Mean and maximum grip strength (kg) from three measurements Used to assess sarcopenia

    Time frame: At baseline and in weeks 6, 7, and 13

  18. Timed Up and Go (TUG) Test

    * Measures mobility and physical function * Procedure: Time (seconds) taken for the patient to: 1. Rise from a chair 2. Walk a short distance 3. Return to the chair

    Time frame: At baseline and in weeks 6, 7, and 13

  19. Change in total fat (Abdominal Ultrasound)

    Total fat measured in centimeters (cm)

    Time frame: At baseline and in weeks 6, 7, and 13

  20. Change in superficial fat (Abdominal Ultrasound)

    Superficial fat measured in centimeters (cm)

    Time frame: At baseline and in weeks 6, 7, and 13

  21. Change in preperitoneal fat (Abdominal Ultrasound)

    Preperitoneal fat measured in centimeters (cm)

    Time frame: At baseline and in weeks 6, 7, and 13

  22. Change in muscle Ultrasound - Area

    Area measured in square centimeters (cm²)

    Time frame: At baseline and in weeks 6, 7, and 13

  23. Change in muscle Ultrasound - Circumference

    Circumference measured in centimeters (cm)

    Time frame: At baseline and in weeks 6, 7, and 13

  24. Change in muscle Ultrasound - X-axis and Y-axis

    X-axis and Y-axis measured in centimeters (cm)

    Time frame: At baseline and in weeks 6, 7, and 13

  25. Change in muscle Ultrasound - Adipose tissue of the rectus femoris of the quadriceps

    Adipose tissue of the rectus femoris of the quadriceps measured in centimeters (cm)

    Time frame: At baseline and in weeks 6, 7, and 13

  26. Change in Glucose

    glucose measured in mg/dl

    Time frame: At baseline and in weeks 6, 7, and 13

  27. Change in Cholesterol

    Cholesterol measured in mg/dl

    Time frame: At baseline and in weeks 6, 7, and 13

  28. Change in Triglycerides

    Triglycerides measured in mg/dl

    Time frame: At baseline and in weeks 6, 7, and 13

  29. Change in Uric acid

    Uric acid measured in mg/dl

    Time frame: At baseline and in weeks 6, 7, and 13

  30. Change in AST

    AST measured in units per litre (U/L)

    Time frame: At baseline and in weeks 6, 7, and 13

  31. Change in ALT

    ALT measured in units per litre (U/L)

    Time frame: At baseline and in weeks 6, 7, and 13

  32. Change in GGT

    GGT measured in units per litre (U/L)

    Time frame: At baseline and in weeks 6, 7, and 13

  33. Change in ALP

    ALP measured in units per litre (U/L)

    Time frame: At baseline and in weeks 6, 7, and 13

  34. Change in insulin

    Insulin measured in units per mililitre (U/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  35. Change in albumin

    Albumin measured in grams per liter (g/l)

    Time frame: At baseline and in weeks 6, 7, and 13

  36. Change in C-reactive protein (CRP)

    C-reactive protein (CRP) measured in milligrams per liter (mg/L)

    Time frame: At baseline and in weeks 6, 7, and 13

  37. Change in Intestinal fatty acid-binding protein (I-FABP)

    Intestinal fatty acid-binding protein (I-FABP) measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  38. Change in zonulin

    Zonulin measured in micrograms per milliliter (μg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  39. Change in musclin

    Musclin measured in nanograms per milliliter (ng/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  40. Change in galectin-3

    Galectin-3 measured in nanograms per milliliter (ng/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  41. Change in myostatin

    Myostatin measured in nanograms per milliliter (ng/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  42. Change in Total antioxidant capacity (TAC)

    Total antioxidant capacity (TAC) measured in nanomoles per microliter (nmol/μL)

    Time frame: At baseline and in weeks 6, 7, and 13

  43. Change in Glutathione peroxidase (GSH-Px)

    Glutathione peroxidase (GSH-Px) measured in milliunits per milliliter (mU/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  44. Change in Superoxide dismutase (SOD)

    Superoxide dismutase (SOD) measured in inhibition rate %

    Time frame: At baseline and in weeks 6, 7, and 13

  45. Change in GLP-1

    GLP-1 measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  46. Change in GIP

    GIP measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  47. Change in PYY

    PYY measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  48. Change in IFN-gamma

    IFN-gamma measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  49. Change in IL-2

    IL-2 measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  50. Change in IL-4

    IL-4 measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  51. Change in IL-6

    IL-6 measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  52. Change in IL-10

    IL-10 measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  53. Change in IL-12p70

    IL-12p70 measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  54. Change in IL-17A

    IL-17A measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  55. Change in TNF-alpha

    TNF-alpha measured in picograms per milliliter (pg/mL)

    Time frame: At baseline and in weeks 6, 7, and 13

  56. Change in stool calprotectin

    Calprotectin measured in micrograms per gram (µg/g)

    Time frame: At baseline and in weeks 6, 7, and 13

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — It is not necessary to reach the objectives of the project

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 28, 2025
StartActual
May 29, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06852014
Lead sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
May 29, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Sep 2, 2025

Study contacts

Gabriel Olveira Fuster, MD, PhD
Contact
gabrielm.olveira.sspa@juntadeandalucia.es
951290343
Gabriel Olveira Fuster, MD, PhD
principal investigator · Hospital Regional Universitario de Málaga, FIMABIS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion